Laronde is the developer of eRNA-based therapeutics, designed to create more reliable and powerful medicines for global use. The company's unique Endless RNA (eRNA) can be programmed to produce a variety of proteins within the body. It is characterized by its persistence, non-immunogenic properties, repeat dosing capabilities, and formulation and delivery flexibility. This enables healthcare professionals and medical companies to develop innovative therapeutics that are poised to become essential future medicines.
BlackRock, CPP Investments, Nextech Invest, Flagship Pioneering, Jameel Investment Management Co., Altitude Life Science Ventures, Federated Kaufmann Fund, Fidelity Management & Research, The Invus Group, Longevity Vision Fund, LifeSci Venture Partners, Quan Capital.